GE Healthcare has announced its Carevance acute-care patient monitoring platform has received a CE mark.
The CE marking allows GE HealthCare to market and distribute Carevance across the European Economic Area (EEA).
The mark indicates that the product meets European safety, health and environmental protection standards.
“As healthcare systems face new demands and challenges, the need for accessible, affordable and trustworthy solutions is crucial,” said Neal Sandy, General Manager of Monitoring Solutions at GE HealthCare. “Carevance brings together reliable clinical parameters, proven acute care workflows and continuous cardiac output monitoring capability, empowering clinicians with real-time insights to support confident decision-making across acute care areas.”
What makes Carevance unique is that it provides cardiac output insights using a clinically validated algorithm with a visual decision support view. This enables clinicians to perform advanced hemodynamic monitoring with more patients, without the barriers of additional hardwares, invasive catheters or high cost.
The features allow clinicians to easily visualise factors that impact hemodynamic status and it offers insights based on latest guidelines. Clinicians can access real-time graphical representation of patient data to monitor and understand changes in hemodynamic stability during and after surgery.
“While current guidelines recommend cardiac output monitoring during high-risk surgery, access to this type of monitoring remains limited,” said Dr Frédéric Michard, founder and Managing Director of MiCo Sàrl. “There is a need to make cardiac output monitoring more accessible, so clinicians have the information they need to understand the underlying mechanisms of hemodynamic instability and make informed therapeutic decisions.”
GE HealthCare will debut Carevance at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Munich from October 25-29.